Vericel Corp (VCEL) shareholders
Close on Nov 17, 2026Market cap $2.96BP/E 137.8Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 7,570,280 | 15.10% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 2,807,242 | 5.60% | 13G (passive) | Sep 30, 2025 |
| Vanguard Capital Management | 2,603,128 | 5.11% | 13G (passive) | Mar 31, 2026 |
| Soleus Capital, LLC Joint filing with Soleus Capital Master Fund, L.P. (5.00%), Soleus Capital Group, LLC (5.00%) and 3 more | 2,549,079 | 5.00% | 13G (passive) | Mar 31, 2026 |
| Conestoga Capital Advisors LLC | 2,495,619 | 5.23% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VCEL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,092,226 | 15.80% | $360.02M | +326,882 | 0.01% |
| State Street Corp | 3,293,975 | 6.43% | $146.58M | +141,845 | 0.00% |
| Congress Asset Management Co /Ma | 2,916,295 | 5.70% | $129.75M | +1,409,377 | 0.80% |
| Vanguard Capital Management LLC | 2,255,728 | 4.41% | $100.36M | +24,972 | 0.00% |
| Conestoga Capital Advisors, LLC | 2,083,832 | 4.07% | $92.71M | −379,480 | 2.02% |
| William Blair Investment Management, LLC | 1,992,855 | 3.89% | $88.66M | +160,146 | 0.27% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,639,988 | 3.20% | $72.96M | −83,584 | 0.07% |
| GW&K Investment Management, LLC | 1,550,497 | 3.03% | $68.98M | −66,358 | 0.54% |
| Soleus Capital Management, L.P. | 1,459,152 | 2.85% | $64.92M | −1,089,927 | 2.24% |
| Geode Capital Management, LLC | 1,341,244 | 2.62% | $59.68M | +86,382 | 0.00% |
| Geneva Capital Management LLC | 1,339,123 | 2.62% | $59.58M | −307,695 | 1.37% |
| Loomis Sayles & Co L P | 1,200,239 | 2.34% | $53.40M | +224,792 | 0.07% |
| Vanguard Portfolio Management LLC | 1,060,753 | 2.07% | $47.19M | +69,127 | 0.00% |
| Bank Of America Corp /De/ | 1,016,184 | 1.98% | $45.21M | −82,587 | 0.00% |
| Dimensional Fund Advisors LP | 906,200 | 1.77% | $40.32M | +61,445 | 0.01% |
| Silvercrest Asset Management Group LLC | 896,651 | 1.75% | $39.89M | −62,556 | 0.26% |
| Royal Bank of Canada | 775,762 | 1.51% | $34.51M | −106,400 | 0.01% |
| Champlain Investment Partners, LLC | 755,828 | 1.48% | $33.63M | −59,345 | 0.86% |
| abrdn plc | 710,238 | 1.39% | $31.60M | +26,113 | 0.04% |
| Nomura Asset Management International Inc. | 664,305 | 1.30% | $29.56M | +33,426 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 319 | 56M | 100.0% | 66 / 121 | 100 / 22 | 7M | 6M |
| Q1 2026 | 279 | 55M | 100.0% | 41 / 105 | 97 / 31 | 11M | 6M |
| Q4 2025 | 273 | 54M | 100.0% | 55 / 100 | 81 / 27 | 6M | 6M |
| Q3 2025 | 250 | 53M | 100.0% | 29 / 86 | 98 / 47 | 5M | 8M |
| Q2 2025 | 273 | 56M | 100.0% | 35 / 130 | 69 / 36 | 7M | 4M |
| Q1 2025 | 277 | 54M | 100.0% | 32 / 114 | 92 / 29 | 4M | 2M |
| Q4 2024 | 278 | 52M | 100.0% | 44 / 102 | 85 / 30 | 4M | 3M |
| Q3 2024 | 268 | 51M | 100.0% | 32 / 102 | 90 / 23 | 12M | 4M |
| Q2 2024 | 261 | 51M | 99.8% | 37 / 95 | 92 / 29 | 4M | 5M |
| Q1 2024 | 257 | 53M | 100.0% | 50 / 83 | 87 / 20 | 6M | 7M |
| Q4 2023 | 227 | 54M | 100.0% | 31 / 60 | 96 / 15 | 4M | 2M |
| Q3 2023 | 213 | 51M | 100.0% | 28 / 77 | 77 / 17 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
265 funds held VCEL in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VCEL | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3,077,197 | 6.01% | $136.90M | 0.12% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,617,188 | 3.16% | $71.95M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,337,684 | 2.61% | $59.51M | 0.07% | Jun 30, 2026 |
| Conestoga Small Cap Fund | 1,307,355 | 2.55% | $58.16M | 2.85% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,194,313 | 2.33% | $53.13M | 0.49% | Jun 30, 2026 |
| Congress Small Cap Growth Fund | 1,090,000 | 2.13% | $50.10M | 2.49% | Jul 31, 2026 |
| Loomis Sayles Small Cap Growth Fund | 649,165 | 1.27% | $28.88M | 1.27% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 583,754 | 1.14% | $25.97M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 563,199 | 1.10% | $25.88M | 0.08% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 475,914 | 0.93% | $21.17M | 0.14% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 469,549 | 0.92% | $20.89M | 0.12% | Jun 30, 2026 |
| William Blair Small Cap Growth Fund | 469,354 | 0.92% | $20.88M | 1.70% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 459,063 | 0.90% | $20.42M | 0.25% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 406,549 | 0.79% | $18.09M | 1.54% | Jun 30, 2026 |
| Brown Capital Management Small Company Fund | 373,015 | 0.73% | $16.60M | 5.17% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dominick Colangelo | President and CEO, Director | 321,270 | 0.63% | Feb 26, 2026 |
| Joseph Anthony Mara Jr | Chief Financial Officer | 16,186 | 0.03% | Nov 12, 2026 |
| Jonathan Siegal | Principal Accounting Officer | 1,259 | 0.00% | Nov 6, 2026 |
| Sean C. Flynn | Chief Legal Officer | 1,990 | 0.00% | Nov 6, 2026 |
| Michael Halpin | Chief Operating Officer | 32,753 | 0.06% | Aug 5, 2026 |
| Jonathan Mark Hopper | Chief Medical Officer | 75,753 | 0.15% | Jun 30, 2026 |
| Karen Mahoney | Chief Human Resources Officer | 2,625 | 0.01% | Dec 12, 2025 |
| Robert L. Zerbe Md | Director | 32,995 | 0.06% | Nov 12, 2026 |
| Kevin F. McLaughlin | Director | 18,300 | 0.04% | Nov 12, 2026 |
| Paul K. Wotton | Director | 26,302 | 0.05% | May 13, 2026 |
| Heidi Hagen | Director | 35,050 | 0.07% | May 1, 2026 |
| Lisa Wright | Director | 15,851 | 0.03% | May 1, 2026 |
| Alan L. Rubino | Director | 64,234 | 0.13% | May 1, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −8 | $59.75 | $478 | 16,186 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 11, 2026 | Option exercise | +8 | $43.63 | $349 | 16,194 |
| Kevin F. McLaughlin Director | Nov 10, 2026 | Sale(10b5-1 plan) | −7,000 | $58.96 | $412.72K | 18,300 |
| Kevin F. McLaughlin Director | Nov 10, 2026 | Option exercise | +7,000 | $13.05 | $91.35K | 25,300 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 9, 2026 | Sale(10b5-1 plan) | −25,000 | $58.26 | $1.46M | 16,186 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 9, 2026 | Option exercise | +25,000 | $43.63 | $1.09M | 41,186 |
| Robert L. Zerbe Md Director | Nov 9, 2026 | Sale(10b5-1 plan) | −2,000 | $57.88 | $115.76K | 32,995 |
| Robert L. Zerbe Md Director | Nov 9, 2026 | Option exercise | +2,000 | $13.05 | $26.10K | 34,995 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 6, 2026 | Sale(10b5-1 plan) | −14,573 | $53.43 | $778.64K | 16,186 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 6, 2026 | Option exercise | +14,573 | $29.82 | $434.57K | 30,759 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 6, 2026 | Sale(10b5-1 plan) | −14,068 | $53.41 | $751.37K | 16,186 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 6, 2026 | Option exercise | +14,068 | $34.90 | $490.97K | 30,254 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 5, 2026 | Sale(10b5-1 plan) | −10,427 | $53.73 | $560.24K | 16,186 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 5, 2026 | Option exercise | +10,427 | $29.82 | $310.93K | 26,613 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 5, 2026 | Sale(10b5-1 plan) | −10,932 | $53.40 | $583.77K | 16,186 |
| Joseph Anthony Mara Jr Chief Financial Officer | Nov 5, 2026 | Option exercise | +10,932 | $34.90 | $381.53K | 27,118 |
| Sean C. Flynn Chief Legal Officer | Nov 5, 2026 | Sale(10b5-1 plan) | −15,000 | $51.92 | $778.80K | 1,990 |
| Sean C. Flynn Chief Legal Officer | Nov 5, 2026 | Option exercise | +15,000 | $16.25 | $243.75K | 16,990 |
| Jonathan Siegal Principal Accounting Officer | Nov 5, 2026 | Sale(10b5-1 plan) | −1,500 | $52.90 | $79.35K | 1,259 |
| Jonathan Siegal Principal Accounting Officer | Nov 5, 2026 | Option exercise | +1,500 | $34.90 | $52.35K | 2,759 |
| Robert L. Zerbe Md Director | Nov 5, 2026 | Sale(10b5-1 plan) | −2,500 | $51.67 | $129.18K | 32,995 |
| Robert L. Zerbe Md Director | Nov 5, 2026 | Option exercise | +2,500 | $13.05 | $32.63K | 35,495 |
| Robert L. Zerbe Md Director | Nov 5, 2026 | Sale(10b5-1 plan) | −500 | $55.00 | $27.50K | 32,995 |
| Robert L. Zerbe Md Director | Nov 5, 2026 | Option exercise | +500 | $13.05 | $6.53K | 33,495 |
| Robert L. Zerbe Md Director | Nov 4, 2026 | Sale(10b5-1 plan) | −2,500 | $45.40 | $113.50K | 32,995 |
| Robert L. Zerbe Md Director | Nov 4, 2026 | Option exercise | +2,500 | $13.05 | $32.63K | 35,495 |
| Kevin F. McLaughlin Director | Aug 12, 2026 | Sale(10b5-1 plan) | −7,000 | $44.53 | $311.71K | 18,300 |
| Kevin F. McLaughlin Director | Aug 12, 2026 | Option exercise | +7,000 | $13.05 | $91.35K | 25,300 |
| Michael Halpin Chief Operating Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −10,000 | $46.84 | $468.40K | 16,394 |
| Michael Halpin Chief Operating Officer | Aug 3, 2026 | Option exercise | +10,000 | $16.66 | $166.60K | 26,394 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −500 | $48.90 | $24.45K | 1,078 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Option exercise | +1,500 | $34.90 | $52.35K | 2,578 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −1,500 | $48.90 | $73.35K | 1,078 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Option exercise | +2,500 | $29.82 | $74.55K | 3,578 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Sale(10b5-1 plan) | −2,500 | $48.90 | $122.25K | 1,078 |
| Jonathan Siegal Principal Accounting Officer | Jul 30, 2026 | Option exercise | +500 | $29.82 | $14.91K | 1,578 |
| Jonathan Siegal Principal Accounting Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −232 | $44.90 | $10.42K | 886 |
| Jonathan Siegal Principal Accounting Officer | Jun 26, 2026 | Option exercise | +2,500 | $29.82 | $74.55K | 3,386 |
| Jonathan Siegal Principal Accounting Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −2,500 | $44.90 | $112.25K | 886 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,000 | $45.00 | $225.00K | 75,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Option exercise | +5,000 | $29.82 | $149.10K | 80,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,000 | $45.00 | $225.00K | 75,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 26, 2026 | Option exercise | +5,000 | $29.82 | $149.10K | 80,753 |
| Joseph Anthony Mara Jr Chief Financial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,000 | $44.75 | $223.75K | 16,009 |
| Sean C. Flynn Chief Legal Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −15,000 | $45.64 | $684.60K | 1,647 |
| Sean C. Flynn Chief Legal Officer | Jun 26, 2026 | Option exercise | +15,000 | $16.25 | $243.75K | 16,647 |
| Michael Halpin Chief Operating Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −10,000 | $40.24 | $402.40K | 16,248 |
| Michael Halpin Chief Operating Officer | Jun 18, 2026 | Option exercise | +10,000 | $16.66 | $166.60K | 26,248 |
| Sean C. Flynn Chief Legal Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −15,000 | $40.21 | $603.15K | 1,647 |
| Sean C. Flynn Chief Legal Officer | Jun 18, 2026 | Option exercise | +15,000 | $16.25 | $243.75K | 16,647 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −4,375 | $35.00 | $153.13K | 75,753 |
| Jonathan Mark Hopper Chief Medical Officer | Jun 2, 2026 | Option exercise | +4,375 | $16.66 | $72.89K | 80,128 |
| Kevin F. McLaughlin Director | May 13, 2026 | Sale(10b5-1 plan) | −3,500 | $32.82 | $114.87K | 18,300 |
| Kevin F. McLaughlin Director | May 13, 2026 | Option exercise | +3,500 | $2.63 | $9.21K | 21,800 |
| Kevin F. McLaughlin Director | May 13, 2026 | Sale(10b5-1 plan) | −3,500 | $32.83 | $114.91K | 18,300 |
| Kevin F. McLaughlin Director | May 13, 2026 | Option exercise | +3,500 | $13.05 | $45.68K | 21,800 |
| Paul K. Wotton Director | May 11, 2026 | Sale | −2,500 | $33.05 | $82.63K | 26,302 |
| Paul K. Wotton Director | May 11, 2026 | Sale | −7,500 | $32.64 | $244.80K | 18,802 |
| Jonathan Siegal Principal Accounting Officer | May 7, 2026 | Sale(10b5-1 plan) | −1,422 | $40.50 | $57.59K | 1,118 |
| Joseph Anthony Mara Jr Chief Financial Officer | May 7, 2026 | Sale(10b5-1 plan) | −5,000 | $40.50 | $202.50K | 21,009 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vericel's stock actually held short. Settlement fails (shares not delivered on time) peaked at 783 shares on Sep 15, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kevin F. McLaughlin Director | Nov 10, 2026 | 7,000 | $408.73K | Nov 10, 2026 | Stock Option Exercise |
| Robert L. Zerbe Md Director | Nov 9, 2026 | 2,000 | $115.75K | Nov 9, 2026 | Stock Option Exercise |
| Joseph Anthony Mara Jr Officer | Nov 9, 2026 | 25,000 | $1.46M | Nov 9, 2026 | Stock Option Exercise |
| Joseph Anthony Mara Jr Officer | Nov 6, 2026 | 28,641 | $1.53M | Nov 6, 2026 | Stock Option Exercise |
| Joseph Anthony Mara Jr Officer | Nov 6, 2026 | 28,641 | $1.53M | Nov 6, 2026 | Stock Option Exercise |
| Joseph Anthony Mara Jr Officer | Nov 5, 2026 | 21,359 | $1.14M | Nov 5, 2026 | Stock Option Exercise |
| Sean C. Flynn Officer | Nov 5, 2026 | 15,000 | $778.86K | Nov 5, 2026 | Stock Option Exercise |
| Robert L. Zerbe Md Director | Nov 5, 2026 | 3,000 | $156.68K | Nov 5, 2026 | Stock Option Exercise |
| Jonathan Siegal Officer | Nov 5, 2026 | 1,500 | $79.35K | Nov 5, 2026 | Stock Option Exercise |
| Robert L. Zerbe Md Director | Nov 4, 2026 | 2,500 | $113.50K | Nov 4, 2026 | Stock Option Exercise |
| Kevin F. McLaughlin Director | Aug 12, 2026 | 7,000 | $308.77K | Aug 12, 2026 | Stock Option Exercise |
| Michael Halpin Officer | Aug 3, 2026 | 10,000 | $459.80K | Aug 3, 2026 | Stock Option Exercise |
| Jonathan Siegal Officer | Jul 30, 2026 | 4,500 | $220.05K | Jul 30, 2026 | Stock Option Exercise |
| Sean C. Flynn Officer | Jun 26, 2026 | 15,000 | $684.66K | Jun 26, 2026 | Stock Option Exercise |
| Joseph Anthony Mara Jr Officer | Jun 26, 2026 | 5,000 | $223.75K | Jun 26, 2026 | Restricted Stock Vesting |
See a number that looks wrong?